by Chris Wack
– Advertisement –
– Advertisement –
Shares of Heartbeam Inc. rose 38% to $6.26 after the company said it had expanded its business to serve the growing cardiac device wearable technology market by bringing clinically relevant clinical information to patients and physicians. Expanded product portfolio pipeline.
Product pipeline advancements allow the addition of arrhythmia detection capabilities to address the multibillion-dollar global market for atrial fibrillation and other arrhythmia monitoring, the company said.
– Advertisement –
The new product portfolio is based on Heartbeam’s new patents, including the 3-lead 3D vector electrocardiogram credit card-sized device, the Heartbeam AIMIGO 3L, which records X, Y, Z cardiac activity and prompts physician review It shows. The plan is for the fourth quarter to submit a 510(k) to the U.S. Food and Drug Administration.
Hartbeam said that to address potential supply-chain issues, procurement of critical components for its planned AIMIGO device production volume for 2023 is in progress.
Last week, the company said it was issued a patent by the US Patent and Trademark Office for technology that enables the creation of 12-lead electrocardiograms synthesized by the Heartbeam AIMIGO device.
Write to Chris Wack at [email protected]
